Testing an immunotherapy drug with or without bladder wash for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bladder cancer called high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
- You must have had BCG (Bacillus Calmette-Guérin) therapy for your bladder cancer and it either didn't work or you couldn't tolerate it.
- You must be 18 years or older and reasonably active (ECOG score 0-2).
- You must not have had previous treatment with a checkpoint inhibitor drug.
- You must not have signs of cancer spreading to muscles or other organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.